ATH-434
Multiple System Atrophy
Alterity TherapeuticsSmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
26 Active assets in the Multiple System Atrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Droxidopa Loma Linda University | Phase 3 | BB |
Zoledronate California Pacific Medical Center Research Institute | Phase 4 | BB |
IOFLUPANE GE Healthcare | Phase 3 | B |
Riluzole King's College London | Phase 3 | B |
Exidavnemab BioArctic AB | Phase 2 | CCC |
View all 40 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →